Platinum Int'l Health Care FundArsn 107 023 530 31 October 2014

Facts		
Portfolio value Fund commenced Minimum investment Regular Investment Plan (min.) Income distribution date Unit valuation Unit prices	\$103.89 mn 10 November 2003 A\$20,000 or NZ\$25,000 A\$200 or NZ\$250 per mth/qtr Annual, 30 June Sydney Business Day App - 1.7814 Red - 1.7725	
Performance ¹		
	FUND %	MSCI %
1 month	(0.75)	2.02
3 months	6.24	13.02
6 months	7.07	16.91
Calendar year to date	4.76	19.68
1 vear	16 71	32 75

10 November 2003	
A\$20,000 or NZ\$25,000	
A\$200 or NZ\$250 per mth/qtr	
Annual, 30 June	
Sydney Business Day	
App - 1.7814 Red - 1.7725	

	FUND %	MSCI %
1 month	(0.75)	2.02
3 months	6.24	13.02
6 months	7.07	16.91
Calendar year to date	4.76	19.68
1 year	16.71	32.75
2 years (compound pa)	24.87	38.10
3 years (compound pa)	22.77	32.48
5 years (compound pa)	17.50	18.76
7 years (compound pa)	10.05	10.82
10 years (compound pa)	8.91	8.56
Since inception (compound pa)	7.92	8.20

Invested positions³ LONG % **CURRENCY %** NET % Australia 1.0 1.0 (0.7)Belgium 1.6 1.6 Canada 0.8 0.8 0.8 Denmark 3.3 3.3 3.3 France 5.8 5.8 Germany 6.9 6.9 Italy 44 44 Japan 5.8 5.8 5.7 Sweden 4.0 4.0 4.3 Switzerland 9.4 9.4 10.8 United Kingdom 8.8 8.8 10.8 United States 28.3 27.3 40.4 80.1 79.2 Brazilian Real 1.0 Euro Currency 21.2 Hong Kong Dollar 0.3 Norwegian Krone 0.7

19.9

100.0

20.8

100.0

Long - 46 stocks Short - 1 stock

Singapore Dollar

Cash

Total

Fees r

Entry fee	Nil
Exit fee	Nil
Management Expense Ratio/	1.54% per annum
Indirect Cost Ratio (MER/ICR)	(inclusive of investment
	& administration costs)
Brokerage paid	Nil
Buy/sell spread	0.5% total



Source: Factset and Platinum

Performance graph²

Top ten positions ⁴			
STOCK	COUNTRY	INDUSTRY	%
AstraZeneca PLC	UK	Health Equip & Servs	4.0
Teva Pharmaceuticals	USA	Pharmaceuticals	3.8
Sanofi SA	France	Pharmaceuticals	3.5
Novartis AG - Registered	Switzerland	Pharmaceuticals	3.1
Biomarin Pharmaceutical Inc	USA	Pharmaceuticals	3.0
Qiagen NV	Germany	Health Equip & Servs	2.5
Incyte Corp Ltd	USA	Biotechnology	2.4
Swedish Orphan Biovitrum AB	3 Sweden	Pharmaceuticals	2.4
Ipsen SA	France	Pharmaceuticals	2.3
BTG PLC	UK	Pharmaceuticals	2.2
Industry breakdown ³			
SECTOR		LONG % N	ET %
Health Care		80.1	79.2

1. Investment returns are calculated using the Fund's unit price and represent the combined income and capital return for the specified period. They are net of fees and costs (excluding the buy-sell spread and any investment performance fee payable), pre-tax, and assume the reinvestment of distributions. The investment returns shown are historical and no warranty can be given for future performance. You should be aware that historical performance is not a reliable indicator of future performance. Due to the volatility of underlying assets of the Fund and other risk factors associated with investing, investment 2. The investment returns depicted in this graph are cumulative on A\$20,000 invested in the Fund since inception relative to the MSCI All Country World Health Care Net Index in A\$. The investment returns are

1.3

100.0

The investment returns depicted in this graph are cumulative on As20,000 invested in the rund since inception relative to the MSCI All Country World Health Care Net index in As3. The investment returns are calculated using the Fund's unit price. They are net of fees and costs (excluding the buy-sell spread and any investment performance fee payable), pre-tax and assume the reinvestment of distributions. It should be noted that Platinum does not invest by reference to the weightings of the Index. Underlying assets are chosen through Platinum's individual stock selection process and as a result holdings will vary considerably to the make-up of the Index. The Index is provided as a reference only.
The "Long %" represents the exposure of physical holdings and long stock derivatives. The "Net %" represents the exposure of physical holdings and both long and short derivatives. The "Currency %" represents the currency exposure for the Fund's Dortfolio, taking into account currency hedging.
Top Ten positions shows the Fund's top long share exposure positions. Long derivative exposures are included, however, short derivative exposures are not.
Platinum Investment Management ("Platinum") is the representable entity and issuer of units in the Platinum International Health"

Platinum Investment Management Limited ABN 25 063 565 006 AFSL 221935, trading as Platinum Asset Management ("Platinum") is the responsible entity and issuer of units in the Platinum International Health Care Fund (the "Fund"). The Platinum Trust Product Disclosure Statement No. 9 and Supplementary PDS ("together PDS") provides details about the Fund. You can obtain a copy of the PDS from Platinum's website www.platinum.com.au, or by contacting Investor Services on 1300 726 700 (Australian investors only), 0800 700 726 (New Zealand investors only), or 02 9255 7500, or via invest@platinum.com.au. Before making any investment decision you need to consider (with your financial adviser) your particular investment needs, objectives and financial circumstances. You should refer to the PDS when deciding to acquire, or continue to hold, units in the Fund.

DISCLAIMER: The information presented in this Fact Sheet is not intended to be advice. It has not been prepared taking into account any particular investor's or class of investor's investment objectives, financial situation or needs, and should not be used as the basis for making investment, financial or other decisions. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. Platinum does not guarantee the repayment of capital, payment of income or the Fund's performance. Platinum is a member of the Platinum Group of companies.